Venetoclax

Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy[1][2][3].

Product Specifications

CAS Number

[1257044-40-8]

Product Name Alternative

ABT-199; GDC-0199; RG7601

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H361, H373

Target

Autophagy; Bcl-2 Family

Type

Reference compound

Related Pathways

Apoptosis; Autophagy

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ABT-199.html

Purity

99.96

Solubility

DMSO : 77.5 mg/mL (ultrasonic) |Ethanol : < 1 mg/mL

Smiles

O=C(NS(=O)(C1=CC=C(NCC2CCOCC2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCN(CC5=C(C6=CC=C(Cl)C=C6)CC(C)(C)CC5)CC4)C=C3OC7=CN=C(NC=C8)C8=C7

Molecular Formula

C45H50ClN7O7S

Molecular Weight

868.44

Precautions

H302, H315, H319, H361, H373

References & Citations

[1]Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19 (2) :202-8.|[2]Peirs S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124 (25) :3738-47.|[3]Bi C, et al. Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. Haematologica. 2017 Apr;102 (4) :755-764.